470P Preclinical assessment of the pharmacokinetics, disposition, and duration of action of the dual alphav-integrin and neuropilin-1 targeting peptide CEND-1

Abstract

CEND-1 (iRGD), a bifunctional cyclic peptide, enhances delivery of co-administered anti-cancer agents by transforming the solid tumour microenvironment into a temporary drug conduit. The present study explored the pharmacokinetic (PK) properties of CEND-1, as well as its distribution, tumor selectivity and duration of action in preclinical tumor models.